Ebola virus vaccine - Novavax

Drug Profile

Ebola virus vaccine - Novavax

Alternative Names: Ebola virus recombinant glycoprotein nanoparticle vaccine; EBOV-GP Vaccine; Recombinant Ebola glycoprotein vaccine; Recombinant Ebola GP vaccine

Latest Information Update: 04 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novavax
  • Class Glycoproteins; Recombinant proteins; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Ebola virus infections

Most Recent Events

  • 23 Jul 2015 Final immunogenicity data from a phase I trial in Ebola virus infections released by Novavax
  • 27 Mar 2015 Pharmacodynamics and adverse events data from a preclinical study in Ebola virus infections (Prevention) released by Novavax
  • 12 Feb 2015 Phase-I clinical trials in Ebola virus infections (Prevention) in Australia (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top